High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results

The inclusion of high-dose therapy/autologous stem cell transplantation (HDT/ASCT) in the initial treatment plan for patients with unfavorable Hodgkin’s lymphoma (HL) has been a matter of debate for the last two decades. In 1991, Carella et al .[1][1] published a pilot study of HDT and ASCT in

[1]  T. Barbui,et al.  Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. , 2008, Blood.

[2]  P. Guglielmelli,et al.  Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal , 2008, Leukemia.

[3]  P. Campbell,et al.  MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. , 2008, Blood.

[4]  P. Campbell,et al.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.

[5]  R. Mesa,et al.  Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.

[6]  P. Guglielmelli,et al.  Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia , 2008, Haematologica.

[7]  Paola Guglielmelli,et al.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.

[8]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[10]  T. Barbui,et al.  Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.

[11]  P. Guglielmelli,et al.  Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. , 2007, British journal of haematology.

[12]  M. Cazzola,et al.  Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.

[13]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[14]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[15]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[16]  D. Steensma,et al.  The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. , 2005, British journal of haematology.

[17]  C. Gisselbrecht,et al.  Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. , 1998, Blood.

[18]  A. Bacigalupo,et al.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. , 1991, Bone marrow transplantation.

[19]  B. Clarkson,et al.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.